OncoChem

Our proprietary radiopharmaceutical, eFAP-51, targets the fibroblast activation protein (FAP) to overcome the tumor microenvironment barrier, a key challenge that has caused previous therapies to fail. Our in vivo studies demonstrated remarkable stability, tumor uptake and retention compared to the reference (FAPI-46), currently in clinical phase. With these promising results, we are seeking €820k to advance eFAP-51 through further validation. This funding will pave the way for the first-in-human clinical trials. Our team is backed by Erasmus MC, a leading institution in nuclear medicine. Dr. Yann Seimbille, Associate Professor and Principal Investigator of Radiopharmaceutical Chemistry, has over 2,000 citations in the field. Dr. Hanyue Ma, a Postdoctoral Researcher in his lab, brings extensive expertise in radiopharmaceutical development. We are at the forefront of innovation and eFAP-51 is a transformative treatment that could save countless lives. Join us in revolutionizing pancreatic cancer treatment.